Oxford BioMedica Extends Agreement With AstraZeneca for Covid-19 Vaccine Facility

By Michael Susin

Oxford BioMedica PLC said Friday that it has signed an extended agreement with AstraZeneca UK Ltd. for the use of its facility to produce AstraZeneca's Covid-19 vaccine.

The U.K. gene and cell therapy group said the new three-year agreement makes the vaccines manufacturing facility Oxbox available to AstraZeneca on an as-needed basis beyond 2022.

The deal represents an expansion of the original deal between the two companies in September 2020, which was originally expected to be complete in the last quarter of 2022, it added.

The company added that the company expects to recognize an aggregate revenue of 30 million pounds ($36.5 million) in the current financial year from AstraZeneca for the batches already manufactured in the first half of 2022.

Write to Michael Susin at [e-mail]

(END) Dow Jones Newswires

07-01-22 0256ET